Patents Examined by Albert M Navarro
  • Patent number: 10780134
    Abstract: The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: September 22, 2020
    Assignee: 4D Pharma Research Limited
    Inventors: George Grant, Angela Margaret Patterson, Imke Mulder, Seanin McCluskey, Emma Raftis
  • Patent number: 10774392
    Abstract: The invention relates to the identification of secretory antibody-bound bacteria in the microbiota in a subject that influence the development and progression of inflammatory diseases and disorders. Thus, the invention relates to compositions and methods for detecting and identifying the constituents of a subject's microbiota, methods of modifying the constituents of the microbiota, and methods for treating inflammatory diseases and disorders in a subject in need thereof.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: September 15, 2020
    Assignee: Yale University
    Inventors: Richard Flavell, Noah Palm, Marcel de Zoete
  • Patent number: 10765719
    Abstract: Prophylactic and/or therapeutic antipathogen agents are provided that disrupt or prevent the formation of at least one homotypic and/or heterotypic protein-protein interaction that has at least one CEA-family protein and that is involved in the establishment and colonization of a pathogen in a suitable host.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: September 8, 2020
    Inventor: Gal Markel
  • Patent number: 10759848
    Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: September 1, 2020
    Assignees: ARSANIS Biosciences GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Valeria Szijárto, Gábor Nagy, Luis Guachalla, Katharina Ramoni, Adriana Badarau, Eszter Nagy, Tim Rollenske, Hedda Wardemann, Irina Mirkina
  • Patent number: 10758600
    Abstract: The present disclosure provides immunogenic materials and methods useful for reducing the risk of fungal infections, particularly valley fever. The disclosure also provides assays for identifying compounds useful to treat valley fever, as well as methods for ameliorating the symptoms of valley fever.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: September 1, 2020
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Marc J. Orbach, Lisa F. Shubitz, Hema P. Narra
  • Patent number: 10729897
    Abstract: Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: August 4, 2020
    Assignee: The Foundry, LLC
    Inventors: Mark E. Deem, Hanson Gifford
  • Patent number: 10717768
    Abstract: Provided herein are novel proteins and protein domains from newly discovered anaerobic fungal species. The anaerobic fungal species have unique enzymatic capabilities, including the ability to digest diverse lignocellulosic biomass feedstocks and to synthesize secondary metabolites. The scope of the invention encompasses novel engineered proteins comprising glycoside hydrolase enzymes, dockerin domains, carbohydrate binding domains, and polyketide synthase enzymes. The invention further encompasses artificial cellulosomes comprising novel proteins and domains of the invention. The scope of the invention further includes novel nucleic acid sequences coding for the engineered proteins of the invention, and methods of using such engineered organisms to degrade lignocellulosic biomass and to create polyketides.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: July 21, 2020
    Assignee: The Regents of the University of California
    Inventors: Michelle O'Malley, Kevin Solomon, Charles Haitjema
  • Patent number: 10711035
    Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: July 14, 2020
    Assignee: GE HEALTHCARE BIOPROCESS R&D AB
    Inventors: Gustav José Rodrigo, Tomas Bjorkman, Mats Ander, Jesper Ulf Hansson
  • Patent number: 10712342
    Abstract: Assays, arrays, and methods for distinguishing a bacterial infection from a viral infection are disclosed. The antibiotic crisis is in part driven by over prescription of antibiotics. There is a tendency, particular in pediatrics, to give an antibiotic even for viral infections. Thus, embodiments herein are directed to the problem of distinguishing a bacterial infection from a viral infection to reduce unnecessary antibiotic usage.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: July 14, 2020
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Stephen Johnston, Lu Wang
  • Patent number: 10702561
    Abstract: Provided herein are pharmaceutical compositions related to a Blautia strain useful as a therapeutic agent.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: July 7, 2020
    Assignee: Evelo Biosciences, Inc.
    Inventors: Brian Goodman, Holly Ponichtera, Andrea Itano, Taylor A. Cormack, Maria Sizova, Valeria Kravitz, Ekaterina Gavrish, Carolina Baez-giangreco
  • Patent number: 10702596
    Abstract: An improved, cost effective and shortened process of purification of the capsular polysaccharide of S. pneumoniae, Group B Streptococcus, H. influenzae, S. typhoid and N. meningitidis is disclosed. The process includes a cocktail of enzyme treatment, tangential flow filtration, and multimodal chromatography purification. For Gram-negative bacteria, endotoxin removal process involves endotrap HD resin. This shortened process achieved the purity required by WHO/EP/BP for the use in human vaccine preparation, with simple steps and higher yield as compared to conventional processes. The steps of the process avoid use of organic solvents such as, for example, alcohol, phenol, and ultracentrifugation that are otherwise expensive and time consuming to perform, and/or health hazards for commercial use. This process disclosed is also simple, efficient, non-toxic, easy to scale-up, and environmentally friendly.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: July 7, 2020
    Assignee: Inventprise, LLC
    Inventors: Subhash V. Kapre, Anup K. Datta
  • Patent number: 10695410
    Abstract: The present invention provides recombinant Listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a PEST-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.
    Type: Grant
    Filed: May 28, 2018
    Date of Patent: June 30, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Matthew Seavey, Yvonne Paterson, Paulo Maciag, Duane Sewell
  • Patent number: 10690671
    Abstract: The present invention provides methods for producing disulfide oxidoreductase A (DsbA) and disulfide oxidoreductase C (DsbC) polypeptides at very high levels of purity. Also provided are ultrapure DsbA and DsbC and methods of using same, e.g., for use in immunoassays to show removal of DsbA and DsbC from biologics produced in bacteria.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: June 23, 2020
    Assignee: Genentech, Inc.
    Inventors: Marc Wong, Liliana T. Yee, Amy Lim, Chris B. Fong
  • Patent number: 10690651
    Abstract: The invention disclosed herein generally relates to methods and kits for diagnosing, assessing disease risk, treating, and preventing bacterial vaginosis (BV) and associated conditions. Additional embodiments include methods for developing metabolic profiles associated with increased disease risk, and developing new approaches to treat BV based on interrupting metabolic networks.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: June 23, 2020
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Sujatha Srinivasan, David N. Fredricks
  • Patent number: 10682403
    Abstract: Nucleic acids include sequences encoding Ehrlichia ruminantium epitopes which induce a CD4 immune response, and sequences encoding Ehrlichia ruminantium epitopes which induce a CD8 immune response. Multi-epitope DNA vaccines include the nucleic acids and polypeptides are encoded by the nucleic acids. Methods of eliciting an immune response against heartwater disease in a subject make use of the nucleic acids, multi-epitope DNA vaccines and polypeptides.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: June 16, 2020
    Assignee: AGRICULTURAL RESEARCH COUNCIL
    Inventors: Alri Pretorius, Frederika Elizabeth Faber, Helena Cornelia Steyn, Junita Liebenberg, Mirinda Van Kleef, Nontobeko Thema, Selaelo Ivy Tshilwane
  • Patent number: 10683330
    Abstract: The present disclosure provides immunogenic compositions against Campylobacter and methods for using the immunogenic composition to generate an immune response against Campylobacter and/or reduce intestinal colonization by Campylobacter.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: June 16, 2020
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Lynn A. Joens, Bibiana Law, Alexandra Armstrong
  • Patent number: 10660956
    Abstract: Embodiments of the present invention provide methods for the treatment or prevention of infection-related immune conditions using compositions comprising IgM.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: May 26, 2020
    Assignee: Grifols Worldwide Operations Limited
    Inventors: Thomas Barnett, David A. Ross
  • Patent number: 10662405
    Abstract: A system for identifying Candida auris is disclosed. The system has two aspects. The first is a positive selection of C. auris based on C. auris's distinctive resistance to quaternary ammonium compounds (especially at elevated incubation temperatures). The second is a negative selection of C. auris based on C. auris's distinctive sensitive to tert-Butyl-hydroperoxide. C. auris can be identified in a sample through use of a positive-selection culture medium, which fosters C. auris colony growth while suppressing growth of other yeasts. The isolate can be confirmed as C. auris through use of a negative-selection culture medium, which suppresses C. auris colony growth while permitting growth of other yeasts.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: May 26, 2020
    Assignee: Santa Fe BioLabs LLC
    Inventor: Wolfram Siede
  • Patent number: 10648981
    Abstract: Provided herein are multiplex assays for detecting antibodies indicative of presence and stage of syphilis infection in an individual. Individuals infected with syphilis produce antibodies directed to syphilis components and the lipid cellular debris associated with the infection. The present disclosure represents the first combination of these diverse antibody targets in a single assay.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: May 12, 2020
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Ravi Kaul, Weiming Zheng, Roger Walker
  • Patent number: 10647765
    Abstract: Herein is reported a fusion polypeptide according to formula I NH2—S2—X1—S1—COOH??(formula I) wherein X1 comprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide, S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and — denotes a peptide bond, wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (PPIase activity) or is derived from the FKBP-fold domain family, wherein X1 is inserted in place of the insert-in-flap-domain of the second polypeptide.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: May 12, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Herbert Andres, David Casagolda Vallribera, Hartmut Duefel, Michael Gerg, Christian Scholz, Michael Schraeml